Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes.
Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own.
On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to make waves in the diabetes industry. However, unlike most companies just entering the space, Embecta comes in with a wealth of experience, according to former Worldwide President of BD Diabetes Care and new Embecta CEO Devdatt Kurdikar, who spoke with Drug Delivery Business News following the spinoff’s completion on April 1.
“Our mission is to develop and provide solutions for people with diabetes, Kurdikar said. “While we might be a newly listed company today, we have a 98-year history of being in this business. Insulin itself has been used to treat diabetes since 1922, and just two years after that, we introduced the first specialized syringe for the delivery of insulin. We’ve been making injection devices for insulin ever since.”
